PDCD1 and breast adenocarcinoma: To address the contribution of host PD‐1 towards anti‐RANKL/PD‐1 BsAb efficacy, we utilised the AT3‐OVAdim breast adenocarcinoma model that is non‐responsive to anti‐PD‐123 in WT mice.